The Philatelist

The issued stamp, shown actual size

Enlarge
  • Commemorative Stamp
  • 16 January 2022

Indian Council of Medical Research COVID-19 Vaccine

COVAXIN, India’s first indigenous COVID-19 vaccine, developed by the Indian Council of Medical Research with Bharat Biotech.

Date of issue January 16, 2022
Denomination Rs. 5
Quantity printed 301920
Printer Security Printing Press, Hyderabad
Perforation 14
Watermark No Watermark
Colours Multicolor
Printing process Wet Offset
Credit Sh. Brahm Prakash
Catalogue codes Michel IN 3758 Yvert et Tellier IN 3437 Stanley Gibbons IN 3799

Notes

Notes from collectors

No public notes on this stamp yet.

Keep your own notes on this stamp, for yourself or to share with other collectors. Sign in

Have a question about this stamp? Start a discussion about it

Record the condition of the stamps in your collection. Sign in

About this stamp

Commemorative Postage Stamp on COVAXIN – India’s First Indigenous COVID-19 Vaccine

In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic, marking the beginning of one of the biggest public health challenges in modern history. With lives disrupted worldwide, the development of a safe and effective vaccine emerged as the most powerful tool to curb transmission and save lives.

India rose to this challenge with resilience and innovation. The journey of COVAXIN, India’s first indigenous COVID-19 vaccine, began in April 2020 after scientists at the Indian Council of Medical Research (ICMR)–National Institute of Virology (NIV), Pune successfully isolated the SARS-CoV-2 virus strain. This strain was then transferred to Bharat Biotech International Ltd (BBIL), a Hyderabad-based company, which embarked on the mission to create a home-grown vaccine in record time.

The Making of COVAXIN

Through rigorous pre-clinical studies and human clinical trials across three phases, two promising formulations were identified. Trials conducted at 25 centers with over 25,800 participants reported an efficacy rate of 77.8% against symptomatic COVID-19, establishing COVAXIN’s strong safety and immunogenicity profile.

Even as new variants like Alpha, Beta, Delta, and others emerged, studies by ICMR-NIV confirmed COVAXIN’s effectiveness against them. This scientific rigor led to 17 research publications in internationally acclaimed journals, solidifying its reputation among the world’s leading vaccines.

A Global Recognition

On 3rd November 2021, COVAXIN became the eighth vaccine worldwide to receive the WHO Emergency Use Listing (EUL), a milestone that placed India firmly on the global scientific map. Achieving this feat within 10 months was a testament to the spirit of Atmanirbhar Bharat (Self-Reliant India) and the dedication of Indian scientists, healthcare workers, and industry leaders.

By the time India celebrated its 75th year of independence, 75% of Indians had been vaccinated, a remarkable public health achievement powered in part by COVAXIN.

Honoring a Milestone with Philately

To celebrate this landmark in India’s scientific and healthcare history, the Department of Posts issued a Commemorative Postage Stamp on COVAXIN. More than just a token of recognition, this stamp is a heartfelt tribute to the tireless efforts of healthcare workers, researchers, and industry partners who stood at the frontlines of the pandemic.

This COVAXIN commemorative stamp not only honors a scientific breakthrough but also symbolizes India’s resilience, innovation, and contribution to the global fight against COVID-19. For philatelists, it represents a unique blend of history, science, and national pride.

For More Information

Read more here:

Related stamps

Stamps sharing its themes, especially Diseases and Medical Science; closest in year first.

All Diseases stamps →
Catalogue Community Learn Shop Sign in